Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China.

ABSTRACT:

Background

Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.

Objectives

Patients with chronic phase CML receiving frontline imatinib treatment.

Design

A retrospective study was used to evaluate the blood concentration, effectiveness, and safety of generic in 170 CML patients.

Methods

Imatinib plasma concentrations were detected by high-performance liquid chromatography-tandem mass spectrometry.

Results

Among the 170 patients, 73 (42.9%) patients treated with branded imatinib as first-line therapy, while 22 (12.9%) switched to generic imatinib during treatment due to economic considerations

SUBMITTER: Cheng F 

PROVIDER: S-EPMC11325334 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature